Skip to content

Trial Summary

This Phase II research project will test the efficacy, safety, and tolerability of an experimental drug combination: either nivolumab and BBI608 or nivolumab and BNC105 in patients with metastatic colorectal cancer who have previously failed standard of care treatment.



ACTRN/NCT /ethics:


Scientific title:

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeBowel and colon
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2018-09-06
Anticipated End Date2022-08-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Phone08 8222 6140
Principal InvestigatorProfessor Tim Price
Recruitment StatusRecruitment on Hold
HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2240
Principal InvestigatorDr Nimit Singhal
Recruitment StatusRecruitment on Hold
HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Phone08 8204 4830
Principal InvestigatorDr Chris Karapetis
Recruitment StatusRecruiting